NeoGenomics, Inc. Appoints Marjorie Green to Board of Directors, Effective June 19, 2025

Published: 2025-06-24 08:20:26 ET NEO

Published on 06/24/2025 at 08:20

NeoGenomics, Inc. announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development.

As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company?s research for its single biggest area of commercial revenue and pipeline investment. Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech.

She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center.

Also the Board of Directors of the company increased the size of the Board of Directors from nine to ten members.